Histopathologic Characteristics of Human Intestine Allograft Acute Rejection in Patients Pretreated with Thymoglobulin or Alemtuzumab

Wu, Tong; Bond, Geoffy; Martin, Dolly; Nalesnik, Michael A.; Demetris, Anthony J.; Abu‐Elmagd, Kareem

doi:10.1111/j.1572-0241.2006.00611.x

Cited by 33 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is also evidence of eosinophil involvement in models of rejection and their activation was shown to be dependent on a Th2 CD4 þ T-cell response (IL-4-dependent) (Braun et al 2000;Surquin et al 2005). Eosinophils were also abundant in intestinal graft infiltrates on T-cell elimination (Wu et al 2006).…”

Section: Effector Mechanisms Of Rejectionmentioning

confidence: 99%

Effector Mechanisms of Rejection

Moreau

Varey

Anegón

et al. 2013

Cold Spring Harbor Perspectives in Medicine

142

136

View full text Add to dashboard Cite

Section: Effector Mechanisms Of Rejectionmentioning

confidence: 99%

Effector Mechanisms of Rejection

Moreau

Varey

Anegón

et al. 2013

Cold Spring Harbor Perspectives in Medicine

142

136

View full text Add to dashboard Cite

“…On H&E stained sections, grading intestinal rejection was based on the following histological criteria (20)(21)(22):…”

Section: Pathologymentioning

confidence: 99%

Evaluation of C4d Deposition and Circulating Antibody in Small Bowel Transplantation

Serre

Canioni

Lacaille

et al. 2008

American Journal of Transplantation

View full text Add to dashboard Cite

Antibody-mediated rejection (AMR) consensus criteria are defined in kidney and heart transplantation by histological changes, circulating donor-specific antibody (DSA), and C4d deposition in affected tissue. AMR consensus criteria are not yet identified in small bowel transplantation (SBTx). We investigated those three criteria in 12 children undergoing SBTx, including one retransplantation and four combined liver-SBTx (SBTx), with a follow-up of 12 days to 2 years. All biopsies (91) were evaluated with a standardized grading scheme for acute rejection (AR), vascular lesions and C4d expression. Sera were obtained at day 0 and during the follow-up. C4d was expressed in 37% of biopsies with or without AR, but in 50% of biopsies with severe vascular lesions. In addition, vascular lesions were always associated with AR and a poor outcome. All children with AR (grade 2 or 3) observed before the third month died or lost the graft. DSA were never found in any studied sera. We found no evidence that C4d deposition was of any clinical relevance to the outcome of SBTx. However, the grading of vascular lesions may constitute a useful marker to identify AR that is potentially resistant to standard treatment, and for which an alternative therapy should be considered.

show abstract

“…The stoma may appear normal or may lose its normal velvety appearance and become friable or ulcerated. Histologically, rejection is graded by the degree of epithelial damage [37]. In mild rejection, epithelial cell apoptosis leads to epithelial cell loss within the deep crypts.…”

Section: Graft Rejectionmentioning

confidence: 99%

Current perspectives on pediatric intestinal transplantation

Mazariegos

Squires²,

Sindhi³

2009

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Irreversible intestinal failure in children is predominantly caused by surgical conditions such as volvulus, necrotizing enterocolitis, and gastroschisis. Functional intestinal failure from motility disorders such as intestinal pseudo-obstruction or enterocyte dysfunction with microvillus inclusion disease also may require intestine replacement. Approved indications for intestinal transplantation include liver dysfunction, loss of major venous access, frequent central line-related sepsis, and recurrent episodes of severe dehydration despite intravenous fluid management. Surgical options include transplantation of the isolated intestine, combined liver-intestine transplantation, or multivisceral transplantation of the stomach, duodenum, pancreas, and small bowel (with or without the liver). Immunosuppression for intestinal transplantation is based on tacrolimus therapy, often with induction immunosuppression using antilymphocyte antibodies (eg, antithymocyte antibody and alemtuzumab). Experience at centers of excellence demonstrates 1- and 5-year patient survival rates of 95% and 77%, respectively, with ongoing investigations focusing on lowering long-term causes of graft loss such as chronic rejection.

show abstract

Histopathologic Characteristics of Human Intestine Allograft Acute Rejection in Patients Pretreated with Thymoglobulin or Alemtuzumab

Cited by 33 publications

References 13 publications

Effector Mechanisms of Rejection

Effector Mechanisms of Rejection

Evaluation of C4d Deposition and Circulating Antibody in Small Bowel Transplantation

Current perspectives on pediatric intestinal transplantation

Contact Info

Product

Resources

About